**[facility name] NOW offering access to novel heart failure therapy**

**through the RESPONDER-HF study**

*Atrial shunting is the newest investigational heart failure therapy intended to reduce symptoms*

*and improve quality of life for patients with few current treatment options.*

**[CITY, COUNTRY]** — [Day MONTH, 2022] – [Facility Name] today announced randomization of its first patient in the RESPONDER-HF trial evaluating the effectiveness of an atrial shunt, an investigational cardiac implant designed to address the frequent hospitalizations and symptoms that limit quality of life in people suffering from heart failure. The hospital is one of [the only/the first] in the [state, region, city] to offer this therapy to its heart failure patients with preserved ejection fraction (HFpEF), the most common type of heart failure, but one for which effective treatments are limited.

“We are proud to be one of the [first/only] hospitals in [Insert Geographic Area] to offer the Corvia® Atrial Shunt through our participation in the RESPONDER-HF trial,” stated [Insert Physician Name, Title]. “Treating heart failure patients who remain symptomatic despite guideline directed medical therapy is challenging and often frustrating because standard treatments, especially those for patients with HFpEF, don’t work well,” [she/he] continued. “Participating in RESPONDER-HF provides my heart failure patients access to a novel, minimally invasive treatment option that has the potential to relieve their breathlessness and fatigue and give them a better quality of life.”

More than 26 million people worldwide have HF,1 and over half of those have HFpEF,2 which has been described as the largest unmet clinical need in cardiovascular medicine. The Corvia Atrial Shunt is a novel cardiac implant that is part of a HF treatment class called *atrial shunting.* It is designed to reduce elevated left atrial pressure (LAP), the primary contributor of HF symptoms in HFpEF patients. The shunt is placed via catheter between the left and right atria, forming a passage that allows blood to flow from the high pressure left atrium to the lower pressure right atrium, with the aim of reducing HF symptoms and hospitalizations, thereby lowering the overall cost of managing HF.

**About the Corvia Atrial Shunt and RESPONDER-HF**

The Corvia Atrial Shunt is the most clinically studied atrial shunt for the reduction of LAP in symptomatic HF patients. It has been implanted in over 550 patients worldwide and reviewed in over 20 academic publications. The RESPONDER-HF trial builds on the extensive data and progressive learnings from the REDUCE LAP-HF II clinical trial, the largest randomized controlled trial of device-based therapy in HFpEF. Results showed that within a large responder population, representing 50% of study patients, treatment with the Corvia Atrial Shunt resulted in a 45% reduction in HF events and a 55% greater improvement in quality of life compared to sham control.3

RESPONDER-HF is a randomized, double-blind, sham-controlled trial including up to 260 patients from centers across the US, Canada, Europe, and Australia. Drs. Sanjiv Shah from Northwestern Memorial Hospital’s Center for Heart Failure and Dr. Martin Leon from Columbia University Irving Medical Center serve as co-principal investigators for the study. For more information, visit [treatmyheartfailure.com.](http://www.treatmyheartfailure.com/)

[Insert Hospital Boilerplate]

[Insert Hospital Media Contacts]

1. Savarese G, Lund LH. Global Public Health Burden of Heart Failure. *Card Fail Rev*. 2017;3(1):7-11.
2. Owan TE et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. *N Engl J Med*. 2006;355:251-259.
3. Borlaug BA et al. Latent Pulmonary Vascular Disease May Alter the Response to Therapeutic Atrial Shunt Device in Heart Failure. *Circulation*. 2022;10.1161.

Corvia is a registered trademark of [Corvia Medical, Inc](https://corviamedical.com/).

##